These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26980460)

  • 1. A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia.
    Hirayasu Y; Sato S; Takahashi H; Iida S; Shuto N; Yoshida S; Funatogawa T; Yamada T; Higuchi T
    BMC Psychiatry; 2016 Mar; 16():66. PubMed ID: 26980460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
    Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
    Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
    Umbricht D; Alberati D; Martin-Facklam M; Borroni E; Youssef EA; Ostland M; Wallace TL; Knoflach F; Dorflinger E; Wettstein JG; Bausch A; Garibaldi G; Santarelli L
    JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.
    Bugarski-Kirola D; Blaettler T; Arango C; Fleischhacker WW; Garibaldi G; Wang A; Dixon M; Bressan RA; Nasrallah H; Lawrie S; Napieralski J; Ochi-Lohmann T; Reid C; Marder SR
    Biol Psychiatry; 2017 Jul; 82(1):8-16. PubMed ID: 28117049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study.
    Bugarski-Kirola D; Wang A; Abi-Saab D; Blättler T
    Eur Neuropsychopharmacol; 2014 Jul; 24(7):1024-36. PubMed ID: 24735806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Bitopertin in Patients with Schizophrenia and Predominant Negative Symptoms: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 2 Trial.
    Hirayasu Y; Sato SI; Shuto N; Nakano M; Higuchi T
    Psychiatry Investig; 2017 Jan; 14(1):63-73. PubMed ID: 28096877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.
    Edgar CJ; Blaettler T; Bugarski-Kirola D; Le Scouiller S; Garibaldi GM; Marder SR
    Psychiatry Res; 2014 Aug; 218(1-2):219-24. PubMed ID: 24809242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.
    Németh G; Laszlovszky I; Czobor P; Szalai E; Szatmári B; Harsányi J; Barabássy Á; Debelle M; Durgam S; Bitter I; Marder S; Fleischhacker WW
    Lancet; 2017 Mar; 389(10074):1103-1113. PubMed ID: 28185672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia.
    Dunayevich E; Buchanan RW; Chen CY; Yang J; Nilsen J; Dietrich JM; Sun H; Marder S
    Schizophr Res; 2017 Apr; 182():90-97. PubMed ID: 27789188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
    Kantrowitz JT; Epstein ML; Lee M; Lehrfeld N; Nolan KA; Shope C; Petkova E; Silipo G; Javitt DC
    Schizophr Res; 2018 Jan; 191():70-79. PubMed ID: 28318835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurophysiological Effects of Bitopertin in Schizophrenia.
    Kantrowitz JT; Nolan KA; Epstein ML; Lehrfeld N; Shope C; Petkova E; Javitt DC
    J Clin Psychopharmacol; 2017 Aug; 37(4):447-451. PubMed ID: 28590364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers.
    Hofmann C; Pizzagalli F; Boetsch C; Alberati D; Ereshefsky L; Jhee S; Patat A; Boutouyrie-Dumont B; Martin-Facklam M
    Psychopharmacology (Berl); 2016 Jul; 233(13):2429-39. PubMed ID: 27178435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
    Schoemaker JH; Jansen WT; Schipper J; Szegedi A
    J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin.
    Rofail D; Regnault A; le Scouiller S; Berardo CG; Umbricht D; Fitzpatrick R
    Qual Life Res; 2016 Jan; 25(1):201-11. PubMed ID: 26143058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan.
    Matsumoto H; Ishigooka J; Ono H; Tadori Y
    Psychiatry Clin Neurosci; 2018 Sep; 72(9):701-712. PubMed ID: 29774635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.